Phase 2
Completed N=625
DAR-901 TB Booster Vaccine to Prevent TB in Adolescents
Source: ClinicalTrials.gov NCT02712424 ↗Enrolled (actual)
625
Serious AEs
1.4%
Results posted
May 2021
Primary outcomePrimary: New Infection With Mycobacterium Tuberculosis — 19; 18 Participants
Summary
DAR-901 booster vaccine or placebo will be administered to adolescents in Tanzania primed with BCG to determine if immunization reduces the risk of TB infection
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY New Infection With Mycobacterium Tuberculosis |
19; 18 | — |
| SECONDARY Persistent New Infection With M. Tuberculosis |
10; 5 | — |
Eligibility Criteria
Inclusion Criteria: Negative IGRA at baseline -
Exclusion Criteria: Pregnancy, serious underlying disease
-
Data sourced from ClinicalTrials.gov (NCT02712424). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.